At its 173rd session in June 2022, the European Pharmacopoeia (Ph. Eur.) Commission decided to start working on mRNA vaccines by establishing the mRNAVAC Working Party, entrusted with elaborating quality standards supporting this emerging field that will be included in the Ph. Eur.

The newly created Working Party’s first task will be to develop a consolidated strategy for future standards addressing these vaccines and their components. The ideas and proposals put forward on this topic during the recent EDQM Symposium on Nanomedicines will be taken into account during the process, as will the experience gained with these vaccines during the pandemic.

Specialists with experience in the formulation of mRNA vaccines and the analytical procedures used in the quality control of these vaccines and their components (e.g. from licensing authorities, official medicines control laboratories, industry or academia) are invited to apply to join the new Working Party.

More information on how to apply can be found here.